Likeness Rx review: a plan ladder you can actually compare

Likeness Rx's GLP-1 page offers compounded semaglutide and tirzepatide, with one-, three-, six- and twelve-month plans. Its public prices are unusually easy to translate into an amount due because the page displays both the billing amount and monthly equivalent. That visibility is useful; it is not an independent assessment of clinical care. [Provider offer]

Two medicines, four purchase periods

For semaglutide, the page lists $139 monthly, $327 every three months, $534 every six months and $948 every twelve months. The annual option is equivalent to $79 per month. For tirzepatide, it lists $199 monthly, $477 every three months, $834 every six months and $1,548 every twelve months; the annual equivalent is $129 per month. These are dated advertised terms, not a personalized quote. [Provider offer]

The page says standard doses, provider review, supplies and shipping are included. It also says subscriptions renew automatically for the selected term and that the first refill is billed early to support continuity. Read the next billing date before ordering, particularly if you choose several months at a time.

What “cancel anytime” leaves unanswered

The ability to stop a future renewal should not be read as a promise to refund an already purchased supply. Obtain the applicable cancellation and refund terms. The provider specifically advertises a full automatic refund if treatment is not prescribed; that scenario is different from stopping after approval. [Provider offer]

The site describes clinician review, care-team messaging and dispensing by licensed US pharmacies. Its GLP-1 page does not name the dispensing pharmacy for an individual order. Ask for that identity and the support arrangements relevant to your prescription. We have not verified individual licenses, batch testing, delivery speed or published customer-review figures.

Keep the badge in proportion

Likeness Rx occupies the third promotional position chosen by this publisher. That placement does not mean its medications have been demonstrated safer or more effective than those offered elsewhere. Its own page states that the compounded products are not FDA-approved. [Provider offer]

FDA's distinction remains the same across every featured compounded offer: approval of a branded medicine does not transfer to a compounded preparation. A clinician should explain the actual treatment choice and whether an approved option can meet your needs. [Regulator guidance]

Compare this billing structure with CoreAge Rx's optional subscriptions. The important difference is the purchase arrangement you accept, not the position of a provider on a page.